BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 4473793)

  • 1. Proceedings: Differentiation between neuroleptic antipsychotic properties and side effects by subgroups of dopaminergic neurons.
    Bunney BS; Aghajanian GK
    Psychopharmacol Bull; 1974 Oct; 10(4):17-8. PubMed ID: 4473793
    [No Abstract]   [Full Text] [Related]  

  • 2. The membrane actions of tranquilizers in relation to neuroleptic-induced parkinsonism and tardive dyskinesia.
    Seeman P; Staiman A; Lee T; Chau-Wong M
    Adv Biochem Psychopharmacol; 1974; 9(0):137-48. PubMed ID: 4151919
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of brain dopamine in the antipsychotic effect of neuroleptics. Evidence from studies of amphetamine-neuroleptic interaction.
    Randrup A
    Mod Probl Pharmacopsychiatry; 1970; 5():60-5. PubMed ID: 5527170
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacology and pathophysiology of dopaminergic neurons.
    Hornykiewicz O
    Adv Cytopharmacol; 1971 May; 1():369-77. PubMed ID: 4950404
    [No Abstract]   [Full Text] [Related]  

  • 5. Dopaminergic neurons: effect of antipsychotic drugs and amphetamine on single cell activity.
    Bunney BS; Walters JR; Roth RH; Aghajanian GK
    J Pharmacol Exp Ther; 1973 Jun; 185(3):560-71. PubMed ID: 4576427
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical evaluation of amantadine in the treatment of extrapyramidal syndromes caused by neuroleptic drugs].
    Bukowczyk A; Wasik A; Horodnicki J
    Psychiatr Pol; 1974; 8(2):143-8. PubMed ID: 4830321
    [No Abstract]   [Full Text] [Related]  

  • 7. A dopaminergic-cholinergic mechanism in production of psychotic symptoms.
    Friedhoff AJ; Alpert M
    Biol Psychiatry; 1973 Apr; 6(2):165-9. PubMed ID: 4709131
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical implications of dopaminergic and cholinergic effects of neuroleptic drugs.
    Stimmel GL
    Hosp Pharm; 1976 Feb; 11(2):50-1, 54-6. PubMed ID: 10235740
    [No Abstract]   [Full Text] [Related]  

  • 9. Neurologic syndromes associated with antipsychotic-drug use.
    N Engl J Med; 1973 Jul; 289(1):20-3. PubMed ID: 4708951
    [No Abstract]   [Full Text] [Related]  

  • 10. Basic principles of rapid neuroleptization.
    Mason AS; Granacher RP
    Dis Nerv Syst; 1976 Oct; 37(10):547-51. PubMed ID: 9267
    [No Abstract]   [Full Text] [Related]  

  • 11. Our experience with octoclothepine therapy.
    Klíma V; Koutská M; Koutský J
    Act Nerv Super (Praha); 1972; 14(2):89-90. PubMed ID: 5040175
    [No Abstract]   [Full Text] [Related]  

  • 12. Proceedings: Interaction of neuroleptic and cholinergic drugs with central dopaminergic mechanisms.
    Kelly P; Miller RJ; Sahakian B
    Br J Pharmacol; 1974 Nov; 52(3):430P-431P. PubMed ID: 4477511
    [No Abstract]   [Full Text] [Related]  

  • 13. [The neuroleptic syndrome. Attempted systematization of primary and secondary effects observed during neuroleptic treatments].
    Lambert PA
    Encephale; 1971; 60(4):335-49. PubMed ID: 5004893
    [No Abstract]   [Full Text] [Related]  

  • 14. Neuroleptic agents of the benzocycloheptapyridoisoquinoline series. A hypothesis on their mode of interaction with the central dopamine receptor.
    Humber LG; Bruderlein FT; Voith K
    Mol Pharmacol; 1975 Nov; 11(6):833-40. PubMed ID: 1239657
    [No Abstract]   [Full Text] [Related]  

  • 15. [Delayed-action neuroleptics (sustained-release neuroleptics). Indications, advantages and side effects].
    Predescu V; Nica-Udangiu St
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1975; 20(4):287-96. PubMed ID: 1085475
    [No Abstract]   [Full Text] [Related]  

  • 16. Basic principles in the use of antipsychotic agents.
    Mason AS
    Hosp Community Psychiatry; 1973 Dec; 24(12):825-9. PubMed ID: 4148176
    [No Abstract]   [Full Text] [Related]  

  • 17. [The side effects of neuroleptic-therapy].
    Fyrö B
    Lakartidningen; 1972 Mar; 69():89-94. PubMed ID: 4664130
    [No Abstract]   [Full Text] [Related]  

  • 18. The pharmacology of tardive dyskinesias.
    Klawans HL
    Am J Psychiatry; 1973 Jan; 130(1):82-6. PubMed ID: 4264755
    [No Abstract]   [Full Text] [Related]  

  • 19. Implications of amphetamine-induced stereotyped behavior as a model for tardive dyskinesias.
    Rubovits R; Klawans HL
    Arch Gen Psychiatry; 1972 Oct; 27(4):502-7. PubMed ID: 5072718
    [No Abstract]   [Full Text] [Related]  

  • 20. [Cellular effect of neuroleptics].
    Kuschinsky K
    Dtsch Med Wochenschr; 1975 Jun; 100(25):1405-8. PubMed ID: 237751
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.